NLRP3 and metabolic dysfunction-associated steatohepatitis: Indeed, prior studies in animal models suggested that inhibition of Nlrp3 ameliorated some histologic components of NASH whereas constitutive activation of Nlrp3 exacerbated NASH features (2, 3, 4, 5, 6, 7, 8, 27).